The Cambria Lord Foundation invites rare disease non-profits nationwide to join in their efforts to establish a National Emergency Treatment Database for rare disease patients. If your organization is interested in joining the coalition, visit their website here, or email email@example.com!
The National Lymphedema Network is asking for help to pass the Lymphedema Treatment Act, S. 2373/H.R. 1608. This legislation seeks to improve coverage for lymphedema treatment by amending Medicare to cover compression supplies. Also supporting are the American Cancer Society, American Academy of Physical Medicine and Rehabilitation, Oncology Nursing Society, American Physical Therapy Association, and American Occupational Therapy Association.
Research!America is asking YOUR organization to sign on to a letter thanking the Senate HELP Committee Chairman Lamar Alexander and Ranking Member Patty Murray for their efforts to advance the Senate Innovations legislative package. These efforts have included negotiating requested additions and changes, securing pay-fors to accommodate an NIH funding boost, and facilitating Senate consideration of the bill under a timetable.
The deadline is 10:00 am on April 26th, so please share this link on social media and help get the word out. Thank you for keeping up the fight on behalf of the rare disease community!
Wednesday, March 23rd: 1:00 pm to 2:00 pm EST
These meetings help facilitate open dialog about legislation that affects the rare disease community. They are open to the public and the media. We ask that media formally announce their participation and refrain from quoting any of the discussion during the meeting. We encourage media to follow up with participants after the meeting for direct quotes.
12-16-15 – Washington, D.C. – In a show of bipartisan support for the rare disease community, members of the House and Senate have come together to form the first bicameral Rare Disease Congressional Caucus.
The Caucus will be critical in raising awareness of the challenges faced by rare disease patients and serve as a platform for giving those individuals a voice in both the House and Senate. In addition, the Caucus will convene briefings throughout the year to educate Congressional staff on topics of importance to the rare disease community.
The Caucus will be co-chaired by Representatives Lance (R-NJ) and Crowley (D-NY) and Senators Hatch (R-UT) and Klobuchar (D-MN).
“Throughout my time in the Senate, I have worked hard to help the 30 million Americans with rare diseases,” Sen. Hatch said. “While we have previously taken important steps, like passing the Orphan Drug Act, the fact that 95 percent of rare diseases currently have no treatment shows that much more needs to be done. Senator Klobuchar has been a terrific partner on legislation to get vital treatments to patients in need, and I am honored to join her as Senate Co-Chairs of the Rare Disease Congressional Caucus.”
“While there are about 7,000 known rare diseases, there are fewer than 500 drugs approved to treat any of those conditions,” Sen. Klobuchar said. “It is critical that we work together to increase the number of safe, effective, and affordable treatments that are available for people with rare diseases. I have long worked with Senator Hatch on this issue and I look forward to continuing this work as a Senate Co-Chair of the Rare Disease Congressional Caucus.”
The Rare Disease Congressional Caucus, originally formed in 2009 by Rep. Upton (R-MI), is currently comprised of 88 Members of the House and will be expanded to include the Senate.
“We are grateful to our House champions and to Senators Hatch and Klobuchar for stepping-up to lead this Caucus on behalf of the rare disease community. We are looking forward to raising awareness about the importance of public policy to spur the development of new therapies for rare disease patients,” said Julia Jenkins, Executive Director of the EveryLife Foundation for Rare Diseases.
Rare Disease Legislative Advocates (RDLA), a program of the EveryLife Foundation for Rare Diseases, will continue to coordinate regular Hill briefings and act as a legislative clearinghouse for the patient community, with the goal of mobilizing patients to be effective legislative advocates (www.rareadvocates.org).
More than 300 patient advocates and industry leaders as well as staff from Capitol Hill and federal agencies joined us last week for the fourth annual RareVoice Awards Gala at Arena Stage in Washington, DC.
Dr. Steve Groft received a Lifetime Achievement award for his dedication to stimulating research and advancing development of therapies during his tenure at the Food and Drug Administration (FDA) and National Institutes of Health (NIH), where he served as Director of the Office of Rare Disease Research from 1993 until his retirement in 2014.
The judges had difficulty selecting the winners among the passionate patient advocates making a difference in states across the country and on Capitol Hill. Patricia Weltin, President and Founder of the Rare Disease United Foundation, received an Abbey for patient advocacy at the state level. Lisa and Max Schill with RASopathies Network received an Abbey for patient advocacy at the federal level for their efforts in support of the 21st Century Cures Act. Ronald Bartek, President and Founder of the Friedreich’s Ataxia Research Alliance, received a Lifetime Achievement Award for his tireless advocacy before Congress as well as the FDA and Social Security Administration.
The Chairman and members of the House Energy and Commerce Committee were recognized for their leadership on the 21st Century Cures Act which has several provisions critical to the rare disease community, including incentives to spur development of new therapies. Representative Fred Upton (R-MI) received a Lifetime Achievement Award. Representative Gus Bilirakis (R-FL), G.K. Butterfield (D-NC) and Diana DeGette (D-CO) were honored with Congressional Leadership Awards. Saul Hernandez, Deputy Chief of Staff and Legislative Director for Representative G.K. Butterfield, and Clay Alspach, Chief Health Counsel of the Energy and Commerce Committee, received Abbeys for their work on behalf of the rare disease community.
Dr. Kakkis, President and Founder of the EveryLife Foundation for Rare Diseases, ended the awards ceremony with a call to action, urging everyone in attendance to contact their Senators to ask that the many provisions of the 21st Century Cures Act supported by the rare disease community be included in Innovation for Healthier Americans, the Senate companion bill.
Thank you to Shire, the Presidential Sponsor, and other sponsors including AbbVie, Alexion, Amgen, Amicus, Genzyme, Novartis, PhRMA, Raptor, and Vertex. Proceeds from the Gala fund Rare Disease Week on Capitol Hill, to be held February 29 through March 3 next year.
Contact: Stephanie Fischer
RareVoice Awards Gala to Honor Rare Disease Advocates and Leaders on Capitol Hill
Washington, DC (November 4, 2015) – Rare Disease Legislative Advocates will honor rare disease advocates and leaders on Capitol Hill at the RareVoice Awards Gala tonight.
Members of Congress will be recognized for their leadership on the 21st Century Cures Act which has several provisions critical to the rare disease community, including incentives to spur development of new therapies. Representative Fred Upton (R-MI) will receive a Lifetime Achievement Award. Representative Gus Bilirakis (R-FL), G.K. Butterfield (D-NC) and Diana DeGette (D-CO) will be honored with Congressional Leadership Awards.
Advocates are hopeful that key provisions of the 21st Century Cures Act will be included in the Senate companion legislation, Innovation for Healthier Americans, and that the Senate will act quickly to advance it. A delay in legislation is a delay in new treatments.
Congressional staff to be honored for efforts on behalf of the rare disease community include Clay Alspach (House Energy and Commerce Committee), Saul Hernandez (Rep. G.K. Butterfield), Sara Mabry (Sen. Bob Casey), Harrison Matheny (Rep. Ryan Zinke), Molly McDonnell (Rep. Leonard Lance), and Carly McWilliams (House Energy and Commerce Committee).
Rare disease advocates to be recognized for federal advocacy include Annette Bakker (Children’s Tumor Foundation), Ronald Bartek (Friedreich’s Ataxia Research Alliance), Noah Coughlan (Run for Rare), Woody Crouch (Sturge-Weber Foundation), Lisa and Max Schill (RASopathies Network), Steve Smith (National MPS Foundation), Steve Walker (Abigail Alliance), and Rob Whan (Caleb’s Crusade).
Rare disease advocates recognized for state advocacy include Sharon King (Taylor’s Tale), Kirsten Norgaard (Adrenal Insufficiency United), Elisa Seeger (Aidan Jack Seeger Foundation), Bruce Thompson (ALS parent advocate), and Patricia Weltin (Rare Disease United Foundation).
A Lifetime Achievement Award will be presented to Dr. Stephen Groft for his dedication to stimulating research and advancing development of therapies during his tenure at the Food and Drug Administration (FDA) and National Institutes of Health (NIH).
Thank you to Shire, the Presidential Sponsor, and other sponsors including AbbVie, Alexion, Amgen, Amicus, Genzyme, Novartis, PhRMA, Raptor, and Vertex.
Additional information is available at http://rarevoiceawards.org/.
Rare Disease Legislative Advocates is a collaborative organization designed to support the advocacy of all rare disease groups. By growing the patient advocacy community and working collectively, we can amplify our many voices to ensure rare disease patients are heard in state and federal government. For more information, visit http://rareadvocates.org/.
Rare Disease Legislative Advocates in coordination with Rare Disease Congressional Caucus Co-Chairs:
Representatives Leonard Lance (R-NJ) and Joe Crowley (D-NY), will host a briefing on:
Precision Medicine: New Frontiers for Rare Diseases
Thursday, November 5th, 2015
12:00 pm – 1:00 pm (lunch provided)
Rayburn House Office Building
Moderator: John Crowley, Chairman & CEO, Amicus Therapeutics
- Matt Might, President, NGLY1.org & Associate Professor, University of Utah
- Erynn Gordon, Director of Clinical Development, 23andMe
- John Stone, Counsel, Committee on Energy and Commerce – U.S. House of Representatives
- Dr. Christopher Austin, Director, National Center for Advancing Translational Sciences, NIH
- Sean Sigmon, Business Development Director, Oracle Health Sciences
2015 Legislative Conference & Lobby Day
FHI 360, 1825 Connecticut Avenue Northwest, Washington DC
Tuesday, February 24, 2015
(Click on the linked titles to view the presentations)
9:15 – 9:30 am Welcome – Overview of the Week
Conference Moderator: Dean Suhr, Genetic Alliance
9:30 – 10:10 am Overview of the 114th Congress
Congress After the Election and a Health Policy Forecast, Joanne Kenen, Health Care Editor, Politico
Congressional Committees That Shape the Future of Health, Nick Mannetto, Principal, FaegreBD Consulting
10:10 – 10:40 am Know Your Lobbying Rights, Siobhan Rausch, Partner, Hogan Lovells
10:40 – 11:40 pm Avenues for Impact
Regulatory Joel White, Founder & President, Horizon Government Affairs
12:10 – 1:30 pm 21st Century Cures Initiative
The Path to 21 Century Cures – Carly McWilliams, Professional Staff – Subcommittee on Health, House Energy & Commerce Committee
OPEN ACT HR 971 (Orphan Product Extensions Now Accelerating Cures & Treatments) – Saul Hernandez, Legislative Director, Office of Rep. Butterfield (D-NC)
CURE (Compassionate Use & Reform & Enhancement) Act HR 909 (Expanded Access) –Andy Taylor, Legislative Director, Office of Rep. McCaul (R-TX)
Dormant Therapies/MODDERN – Eric Gascho, Assistant Vice President for Government Affairs, National Health Council
Advancing Research for Neurological Diseases Act HR 292 – Jennifer Sheridan Palute, Policy Director, Parkinson’s Action Network
1:30 – 2:10 pm Prepping for your Hill Meetings
Lobbying Tips & Overview of Schedules Stephanie Vance, Owner & Founder, Advocacy Associates
Giving your two minute personal story – Kristine PJ Caalim, Founder, Zequing For a Cure
A Symbol for the Rare Disease Community: Gene Ribbons – Carrie Ostrea, Director of Advocacy, Global Genes
Leave behinds & the Caucus Ask – Andy Russell, Associate Director, EveryLife Foundation for Rare Diseases
2:10 – 2:40 pm Break & Distribution of Hill Day Schedules
2:40 – 3:30 pm Break-Out Skill Training Workshops
Starting your own Non-profit to Grow your Advocacy Impact –Barbara Lavery, Vice President of Strategic Alliances, Global Genes Project & Mike Illions, Vice President, Pediatric Hydrocephalus Organization
- Tips and tools for getting your rare disease organization to the next level. Learn about obtaining 501c3 status, creating a mission, vision, and a board of directors. Essential skills for any aspiring organization.
Polish & Practice your Presentation Pitch – Joe LaMontain, Vice President, Reingold Inc.
- Learn about persuasive and effective communication for maximum advocacy impact. Get tips for making a lasting impression and laying the groundwork to build a first-time meeting into a lasting relationship.
Introducing Legislation – Julia Jenkins, Executive Director, EveryLife Foundation
- Hear about the do’s and don’ts for introducing legislation, coalition building, and how to move a bill through the legislative process.
Social Media Advocacy – Joel Cohen, Non-Profits, Politics & Advocacy, Facebook
- Learn some insider tips for leveraging social media to raise awareness and build an action network for your cause.
3:40 – 4:30 pm State/Regional Break-Out Sessions Practice Meetings
4:40 pm Closing Remarks
5:00 pm End Conference
Thank you for attending this year’s annual Rare Disease Legislative Conference in Washington D.C. We were proud to bring together over 300 members of the rare disease community from across the country to share their unique stories, ideas, and make our collective voice heard on Capitol Hill.
Your presence helped to make this event a great success and your enthusiasm and positive spirit helped make our time together both productive and fun. We want you to continue to be engaged with RDLA and your legislative representatives, so please follow up with the offices you visited (if you haven’t already) and send us stories and pictures of your meetings either by email or use the AdvocacyApp (https://advocacyassociates.constituentvoice.net//). Help spread the word with advocates that weren’t able to make our conference by writing blog posts and testimonials, and sharing your photos on social media. Also, we are pleased to let you know that presentations and photos from this year’s conference will be available on our website soon, so stay tuned and stay engaged with RDLA. Throughout the year we have opportunities for advocates to learn about the most recent Rare Disease Legislation (monthly webinars), meet with their representatives (In-District Lobby Days), and celebrate those who have raised the voice of the rare disease community (RareVoice Awards).
If you attended the conference please take a moment to fill out our quick survey regarding your conference experience. Your feedback is critical in our ongoing effort to improve this annual event.
Thank you again for being part of such a wonderful conference experience!